Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. Chemotherapy. The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States



Survival: 19.0 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: United States
   
City/State/Province: Houston, Texas
   
Hospital: The University of Texas M. D. Anderson Cancer Center
   
Journal: Link
   
Date: 11/2008

Description:
Patients:
This phase 2 study involved 31 relapsed or refractory aggressive mantle cell lymphoma patients. The median patient age was 63 years and the male to female ratio was 5 to 1.

Treatment:
Patients were treated with the biologic therapy agent rituximab, the chemotherapy combination called CVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone), and the chemotherapy drug methotrexate-cytarabine.

Toxicities:
The most severe toxicities were grade 4 neutropenia and thrombocytopenia. Grade 2 swelling, vomiting, and constipation were also reported.

Results:
The median overall survival was 19 months.

Support:
Some of the authors have received funding from various pharmaceutical companies.

Correspondence: Dr. Jorge E. Romaguera; email: jromague@mdanderson.org

E-mail to a Friend Email Physician More Information